DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by:1
raised blood eosinophils (EOS)
and/or raised fraction of exhaled nitric oxide (FeNO)
who are inadequately controlled with high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment
Over 48,000 patients aged 12 years or older have been prescribed DUPIXENT for moderate-to-severe asthma in North America and Europe as of July 20211
More than 320,000 patients have been prescribed DUPIXENT in North America and Europe as of July 2021, across indications1
DUPIXENT can be self-injected or administrated by a caregiver via a pre-filled pen or pre-filled syringe after appropriate training by a healthcare professional (HCP)2
200 mg for severe asthma patients excluding oral corticosteroid
(OCS)-dependent patients2
300 mg for OCS-dependent severe asthma patients and patients requiring DUPIXENT to control comorbid moderate-to-severe atopic dermatitis (AD) or severe Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)2
Introducing the DUPIXENT pre-filled pen
DUPIXENT pre-filled pen can be used to ensure
patients administer DUPIXENT as directed2
DUPIXENT can be administered with a pre-filled pen or pre-filled syringe2
Learn how to administer DUPIXENT using the pre-filled pen or pre-filled syringe2
How to store DUPIXENT2
Keep the pre-filled pen(s) or pre-filled syringe(s) and all medicines out of the reach of children
Keep unused pre-filled pens or pre-filled syringes in the original carton and store in the refrigerator between 2°C and 8°C
Store pre-filled pens or pre-filled syringes in the original carton to protect it from light
Do not keep pre-filled pens or pre-filled syringes at room temperature (<25ºC) for more than 14 days2
Do not freeze the pre-filled pen or pre-filled syringe2
Do not shake the pre-filled pen or pre-filled syringe at any time2
Do not place the pre-filled pen or pre-filled syringe into direct sunlight2
Do not heat the pre-filled pen or pre-filled syringe2
Exacerbations and lung function
DUPIXENT can improve exacerbations and lung function of 12+ years old patients with severe asthma
- Sanofi Data on File. MAT-IE-2000837(v2.0). July 2021.
- Sanofi Genzyme. Dupixent Summary of Product Characteristics, June 2022.
- Dupixent Patient Information Leaflet for pre-filled pen. Available at: https://www.medicines.org.uk/emc/product/11321/pil. Date accessed: June 2022.
- Dupixent Patient Information Leaflet for pre-filled syringe. Available at: https://www.medicines.org.uk/emc/product/8553/pil. Date accessed: June 2022.
AD, atopic dermatitis; CRSwNP, Chronic Rhinosinusitis with Nasal Polyposis; HCP, healthcare professional; OCS, oral corticosteroids.
References
MAT-GB-2004975(v7.0) | Date of preparation: June 2022